Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Boissel

Showing results (31-40 of 323) with videos related to

Pageof 33
Sort By:
Respiration; International Review of Thoracic Diseases|January 1, 1994
OM-85 BV: primary versus secondary preventionJ P Collet, J P Boissel
Fundamental & Clinical Pharmacology|January 1, 1990
The place of simultaneous pharmacokinetic pharmacodynamic modeling in new drug development: trends and perspectivesP Girard, P Nony, J P Boissel
European Journal of Clinical Pharmacology|January 1, 1980
The phenomenon of regression to the mean and clinical investigation of blood cholesterol lowering drugsJ P Boissel, B Duperat, A Leizorovicz
The American Journal of Cardiology|March 1, 1997
Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prévention Secondaire de l'InfarctusM Cucherat, J P Boissel, A Leizorovicz
Therapie|January 1, 1997
[Role of meta-analysis in the definition of target population in therapy]J P Boissel, M Cucherat, F Gueyffier
Archives Des Maladies Du Coeur Et Des Vaisseaux|August 1, 1997
[The Hypertension Cochrane Review Group. Presentation and user's guide]F Gueyffier, J P Boissel, M Haugh
Fundamental & Clinical Pharmacology|January 1, 1990
Which experimental design for phase I clinical trials? Proposal for an investigational approachI Durieu, P Girard, J P Boissel
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 10, 1998
Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III)U Förstermann, J P Boissel, H Kleinert
Archives Des Maladies Du Coeur Et Des Vaisseaux|February 1, 1991
[Class I anti-arrhythmia agents and prevention of sudden death following myocardial infarction]J P Boissel, M Lièvre, Y Rosenberg
Therapie|May 1, 1996
[Hierarchies according to the level of evidence of source data, before their integration in the synthesis, in the matter of therapeutic efficacy]N Bossard, J P Boissel, G Duru
Pageof 33

Showing results (31-40 of 323) with videos related to

Sort By:
Pageof 33
Respiration; International Review of Thoracic Diseases|January 1, 1994
OM-85 BV: primary versus secondary preventionJ P Collet, J P Boissel
Fundamental & Clinical Pharmacology|January 1, 1990
The place of simultaneous pharmacokinetic pharmacodynamic modeling in new drug development: trends and perspectivesP Girard, P Nony, J P Boissel
European Journal of Clinical Pharmacology|January 1, 1980
The phenomenon of regression to the mean and clinical investigation of blood cholesterol lowering drugsJ P Boissel, B Duperat, A Leizorovicz
The American Journal of Cardiology|March 1, 1997
Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prévention Secondaire de l'InfarctusM Cucherat, J P Boissel, A Leizorovicz
Therapie|January 1, 1997
[Role of meta-analysis in the definition of target population in therapy]J P Boissel, M Cucherat, F Gueyffier
Archives Des Maladies Du Coeur Et Des Vaisseaux|August 1, 1997
[The Hypertension Cochrane Review Group. Presentation and user's guide]F Gueyffier, J P Boissel, M Haugh
Fundamental & Clinical Pharmacology|January 1, 1990
Which experimental design for phase I clinical trials? Proposal for an investigational approachI Durieu, P Girard, J P Boissel
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 10, 1998
Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III)U Förstermann, J P Boissel, H Kleinert
Archives Des Maladies Du Coeur Et Des Vaisseaux|February 1, 1991
[Class I anti-arrhythmia agents and prevention of sudden death following myocardial infarction]J P Boissel, M Lièvre, Y Rosenberg
Therapie|May 1, 1996
[Hierarchies according to the level of evidence of source data, before their integration in the synthesis, in the matter of therapeutic efficacy]N Bossard, J P Boissel, G Duru
Pageof 33